Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 1, 2011, Pages 128-136

  Lee, Hae Nam ^a   Lee, Keun Ho ^b   Lee, Dae Woo ^a   Lee, Yong Seok ^c   Park, Eun Kyung ^c   Park, Jong Sup ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Daejeon St Mary's Hospital   (South Korea)

Author keywords

Adjuvant chemoradiation; Cervical cancer; Triweekly combination; Weekly cisplatin

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; HYSTERECTOMY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 79951503189     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318200f7c5     Document Type: Article

References (15)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-841.
2. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613. (Pubitemid 30220538)
3. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177-183. (Pubitemid 29215728)
4. Morrow P. Is pelvic radiation beneficial in the postoperative management of stage Ib squamous cell carcinoma of the cervix with pelvic node metastasis treated by radical hysterectomy and pelvic lymphadenectomy? A report from the Presidential Panel at the 1979 Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol. 1980;10:105-110.
5. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153. (Pubitemid 29177873)
6. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIBYIVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348. (Pubitemid 29220838)
7. Alvarez RD, Soong SJ, Kinney WK, et al. Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol. 1989;35:130-135. (Pubitemid 19268543)
8. Panici PB, Greggi S, Scambia G, et al. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol. 1991;41:212-216.
9. Sardi J, Sananes C, Giaroli A, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol. 1993;49:156-165. (Pubitemid 23169984)
10. Panici PB, Scambia G, Baiocchi G, et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Cancer. 1991;67:372-379.
11. Hwang YY, Moon H, Cho SH, et al. Ten-year survival of patients with locally advanced, stage Ib - IIb cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol. 2001;82:88-93. (Pubitemid 32634959)
12. Lee SB, Tong SY, Kim JJ, et al. Caspase-independent autophagic cytotoxicity in etoposide-treated CaSki cervical carcinoma cells. DNA Cell Biol. 2007;26:713-720.
13. Bae JH, Lee SJ, Lee A, et al. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer. Gynecol Oncol. 2008;111:444-448.
14. Al-Saleh E, Hoskins PJ, Pike JA, et al. Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma. Gynecol Oncol. 1997;64:468-472. (Pubitemid 27120438)
15. SundstrLm S, Bremnes RM, Kaasa S, et al. Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002;20:4665-4672. (Pubitemid 36025283)